Current Status of Multiple Drug Molecules, and Vaccines: An Update in SARS-CoV-2 Therapeutics

Ramesh Kandimalla; Albin John; Chandrika Abburi; Jayalakshmi Vallamkondu; P. Hemachandra Reddy

doi:10.1007/s12035-020-02022-0

Current Status of Multiple Drug Molecules, and Vaccines: An Update in SARS-CoV-2 Therapeutics

Ramesh Kandimalla
, Albin John
, Chandrika Abburi
, Jayalakshmi Vallamkondu
, P. Hemachandra Reddy

Research output: Contribution to journal › Review article › peer-review

46 Scopus citations

Abstract

The coronavirus disease of 2019 (COVID-19) is a pandemic disease that has taken the lives of many around the world. It is caused by severe acute respiratory syndrome-corona virus-2 (SARS-CoV-2). To date, the USA, Italy, Spain, France, Russia, and the UK have been hit the hardest by the virus. However, death counts are still rising. Some nations have managed to “flatten” the death rate via protective measures such physical distancing, quarantine measures, and therapeutic management. The structure of the SARS-CoV-2 virus comprises of S proteins, M proteins, E proteins, hemagglutinin esterases, nucleocapsid proteins, and a 30-kb RNA genome. Viral proteases cleave these polyproteins and RNA-dependent polymerases replicate the genome. Currently, there are no effective therapies against this new disease. Numerous investigators are developing novel protease inhibitors, some of which have made it into clinical trials. Researchers are also attempting to develop a vaccine. In this review paper, we discuss the latest therapeutic developments against COVID-19. [Figure not available: see fulltext.]

Original language	English (US)
Pages (from-to)	4106-4116
Number of pages	11
Journal	Molecular Neurobiology
Volume	57
Issue number	10
DOIs	https://doi.org/10.1007/s12035-020-02022-0
State	Published - Oct 1 2020

Funding

Authors thank DBT for awarding Ramalingaswami Re-entry Fellowship to RK. Authors also thank NIH for supporting PHR with the following grants: R01AG042178, R01AG47812, R01NS105473, and AG060767.

Funders	Funder number
Author National Institutes of Health National Institutes of Health National Institutes of Health National Institutes of Health The Bev Hartig Huntington's Disease Foundation National Institutes of Health	R01AG47812, R01NS105473, AG060767, R01AG042178
U.S. Department of Health and Human Services	and AG060767

Keywords

HCQ
Protease inhibitor
Remdesivir
SARS-CoV-2
Vaccines

ASJC Scopus subject areas

Neuroscience (miscellaneous)
Neurology
Cellular and Molecular Neuroscience

Access to Document

10.1007/s12035-020-02022-0

Cite this

@article{e9196383c9a5481c832854bf9b82ff14,

title = "Current Status of Multiple Drug Molecules, and Vaccines: An Update in SARS-CoV-2 Therapeutics",

abstract = "The coronavirus disease of 2019 (COVID-19) is a pandemic disease that has taken the lives of many around the world. It is caused by severe acute respiratory syndrome-corona virus-2 (SARS-CoV-2). To date, the USA, Italy, Spain, France, Russia, and the UK have been hit the hardest by the virus. However, death counts are still rising. Some nations have managed to {\textquotedblleft}flatten{\textquotedblright} the death rate via protective measures such physical distancing, quarantine measures, and therapeutic management. The structure of the SARS-CoV-2 virus comprises of S proteins, M proteins, E proteins, hemagglutinin esterases, nucleocapsid proteins, and a 30-kb RNA genome. Viral proteases cleave these polyproteins and RNA-dependent polymerases replicate the genome. Currently, there are no effective therapies against this new disease. Numerous investigators are developing novel protease inhibitors, some of which have made it into clinical trials. Researchers are also attempting to develop a vaccine. In this review paper, we discuss the latest therapeutic developments against COVID-19. [Figure not available: see fulltext.]",

keywords = "HCQ, Protease inhibitor, Remdesivir, SARS-CoV-2, Vaccines",

author = "Ramesh Kandimalla and Albin John and Chandrika Abburi and Jayalakshmi Vallamkondu and Reddy, \{P. Hemachandra\}",

note = "Publisher Copyright: {\textcopyright} 2020, Springer Science+Business Media, LLC, part of Springer Nature.",

year = "2020",

month = oct,

day = "1",

doi = "10.1007/s12035-020-02022-0",

language = "English (US)",

volume = "57",

pages = "4106--4116",

journal = "Molecular Neurobiology",

issn = "0893-7648",

publisher = "Springer",

number = "10",

}

TY - JOUR

T1 - Current Status of Multiple Drug Molecules, and Vaccines

T2 - An Update in SARS-CoV-2 Therapeutics

AU - Kandimalla, Ramesh

AU - John, Albin

AU - Abburi, Chandrika

AU - Vallamkondu, Jayalakshmi

AU - Reddy, P. Hemachandra

PY - 2020/10/1

Y1 - 2020/10/1

N2 - The coronavirus disease of 2019 (COVID-19) is a pandemic disease that has taken the lives of many around the world. It is caused by severe acute respiratory syndrome-corona virus-2 (SARS-CoV-2). To date, the USA, Italy, Spain, France, Russia, and the UK have been hit the hardest by the virus. However, death counts are still rising. Some nations have managed to “flatten” the death rate via protective measures such physical distancing, quarantine measures, and therapeutic management. The structure of the SARS-CoV-2 virus comprises of S proteins, M proteins, E proteins, hemagglutinin esterases, nucleocapsid proteins, and a 30-kb RNA genome. Viral proteases cleave these polyproteins and RNA-dependent polymerases replicate the genome. Currently, there are no effective therapies against this new disease. Numerous investigators are developing novel protease inhibitors, some of which have made it into clinical trials. Researchers are also attempting to develop a vaccine. In this review paper, we discuss the latest therapeutic developments against COVID-19. [Figure not available: see fulltext.]

AB - The coronavirus disease of 2019 (COVID-19) is a pandemic disease that has taken the lives of many around the world. It is caused by severe acute respiratory syndrome-corona virus-2 (SARS-CoV-2). To date, the USA, Italy, Spain, France, Russia, and the UK have been hit the hardest by the virus. However, death counts are still rising. Some nations have managed to “flatten” the death rate via protective measures such physical distancing, quarantine measures, and therapeutic management. The structure of the SARS-CoV-2 virus comprises of S proteins, M proteins, E proteins, hemagglutinin esterases, nucleocapsid proteins, and a 30-kb RNA genome. Viral proteases cleave these polyproteins and RNA-dependent polymerases replicate the genome. Currently, there are no effective therapies against this new disease. Numerous investigators are developing novel protease inhibitors, some of which have made it into clinical trials. Researchers are also attempting to develop a vaccine. In this review paper, we discuss the latest therapeutic developments against COVID-19. [Figure not available: see fulltext.]

KW - HCQ

KW - Protease inhibitor

KW - Remdesivir

KW - SARS-CoV-2

KW - Vaccines

UR - https://www.scopus.com/pages/publications/85087983896

UR - https://www.scopus.com/pages/publications/85087983896#tab=citedBy

U2 - 10.1007/s12035-020-02022-0

DO - 10.1007/s12035-020-02022-0

M3 - Review article

AN - SCOPUS:85087983896

SN - 0893-7648

VL - 57

SP - 4106

EP - 4116

JO - Molecular Neurobiology

JF - Molecular Neurobiology

IS - 10

ER -

Current Status of Multiple Drug Molecules, and Vaccines: An Update in SARS-CoV-2 Therapeutics

Abstract

Funding

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this